DarwinHealth is an American biomedical company that uses algorithms and mathematical models in combination with wet lab experiments to develop cancer medicine.
[6] The company's approach is to utilize algorithms developed in the Califano Lab at Columbia University to help physicians identify transcription factors in tumors and to predict potential drug targets and treatments.
[8] In 2019, DarwinHealth and Celgene entered into a scientific collaboration to prioritize the oncology-relevant bioactivity of oncology compounds using its algorithmic framework with the goal of identifying their mechanism of action (MOA) against Master Regulator (MR) proteins.
[11] In 2016, Andrea Califano of DarwinHealth, together with his colleague Mariano Alvarez, introduced the concept of "oncotecture" in a paper published in Nature Reviews Cancer.
[7] The protocol identifies tumor checkpoint MRs from patient samples and selects relevant in vitro and in vivo models to discern tissue-specific drug MOAs.